GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Treatment com AI Inc (XCNQ:TRUE) » Definitions » EV-to-EBITDA

Treatment com AI (XCNQ:TRUE) EV-to-EBITDA : -4.98 (As of May. 31, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Treatment com AI EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Treatment com AI's enterprise value is C$18.15 Mil. Treatment com AI's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-3.65 Mil. Therefore, Treatment com AI's EV-to-EBITDA for today is -4.98.

The historical rank and industry rank for Treatment com AI's EV-to-EBITDA or its related term are showing as below:

XCNQ:TRUE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.35   Med: -2.18   Max: -0.66
Current: -4.98

During the past 5 years, the highest EV-to-EBITDA of Treatment com AI was -0.66. The lowest was -5.35. And the median was -2.18.

XCNQ:TRUE's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Healthcare Providers & Services industry
Industry Median: 12.825 vs XCNQ:TRUE: -4.98

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-31), Treatment com AI's stock price is C$0.48. Treatment com AI's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.410. Therefore, Treatment com AI's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Treatment com AI EV-to-EBITDA Historical Data

The historical data trend for Treatment com AI's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Treatment com AI EV-to-EBITDA Chart

Treatment com AI Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - -3.85 -1.04 -4.29

Treatment com AI Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.04 -1.55 -1.99 -3.34 -4.29

Competitive Comparison of Treatment com AI's EV-to-EBITDA

For the Health Information Services subindustry, Treatment com AI's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Treatment com AI's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Treatment com AI's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Treatment com AI's EV-to-EBITDA falls into.



Treatment com AI EV-to-EBITDA Calculation

Treatment com AI's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=18.148/-3.646
=-4.98

Treatment com AI's current Enterprise Value is C$18.15 Mil.
Treatment com AI's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Treatment com AI  (XCNQ:TRUE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Treatment com AI's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.48/-0.410
=At Loss

Treatment com AI's share price for today is C$0.48.
Treatment com AI's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.410.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Treatment com AI EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Treatment com AI's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Treatment com AI (XCNQ:TRUE) Business Description

Traded in Other Exchanges
Address
838 West Hastings Street, Suite 700, Vancouver, BC, CAN, V6C 0A6
Treatment com AI Inc operates in the business of providing personalized health care information that is relevant and trustworthy empowering patients to make responsible, informed decisions about their health while improving communications, reducing costs and in-clinic wait times for medical practitioners.
Executives
Essam Hamza Director, Senior Officer